Vincristine sulfate
- CAS No.
- 2068-78-2
- Chemical Name:
- Vincristine sulfate
- Synonyms
- oncovin;VCR;NovopharM;VINCRISTINE SULPHATE;LEUROCRISTINE SULFATE;VINCRISTINE SULFATE USP;VINCRISTINE SULFATE SALT;onkovin;nsc67574;Vincrisul
- CBNumber:
- CB9479083
- Molecular Formula:
- C46H58N4O14S
- Molecular Weight:
- 923.04
- MOL File:
- 2068-78-2.mol
- Modify Date:
- 2024/7/4 21:45:01
| Melting point | 300 °C |
|---|---|
| Boiling point | 273-281 °C |
| alpha | D26 +8.5° (c = 0.8) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | methanol: soluble20mg/mL |
| form | lyophilized powder |
| color | white to off-white |
| Water Solubility | >=1 g/100 mL at 24 ºC |
| BRN | 3924631 |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 3 months. |
| InChIKey | AQTQHPDCURKLKT-HSMPTBRCNA-N |
| IARC | 3 (Vol. 26, Sup 7) 1987 |
| EPA Substance Registry System | Vincristine sulfate (2068-78-2) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS06,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H300-H341-H361fd | |||||||||
| Precautionary statements | P202-P264-P270-P280-P301+P310-P405 | |||||||||
| Hazard Codes | T | |||||||||
| Risk Statements | 61-36/37/38-63-23/24/25-68-62-25 | |||||||||
| Safety Statements | 22-24/25-53-45-37/39-26-36/37/39-36/37 | |||||||||
| RIDADR | UN 2811 6.1/PG 2 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | OH6340000 | |||||||||
| F | 8-10 | |||||||||
| HazardClass | 6.1(a) | |||||||||
| PackingGroup | II | |||||||||
| HS Code | 29399990 | |||||||||
| Toxicity | LD50 intraperitoneal in mouse: 3mg/kg | |||||||||
| NFPA 704 |
|
Vincristine sulfate price More Price(7)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | V8879 | Vincristine sulfate salt 95.0-105.0% (HPLC), powder or crystals | 2068-78-2 | 1MG | ₹12037.4 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | V8879 | Vincristine sulfate salt 95.0-105.0% (HPLC), powder or crystals | 2068-78-2 | 5MG | ₹13953.43 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | V8879 | Vincristine sulfate salt 95.0-105.0% (HPLC), powder or crystals | 2068-78-2 | 25MG | ₹56874.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | V8388 | Vincristine sulfate meets USP testing specifications | 2068-78-2 | 1MG | ₹11734.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | V8388 | Vincristine sulfate meets USP testing specifications | 2068-78-2 | 5MG | ₹30602.28 | 2022-06-14 | Buy |
Vincristine sulfate Chemical Properties,Uses,Production
Chemical Properties
Crystalline Solid
Uses
Vincristine sulfate, is used as an anticancer agent, microtubule disrupter, Induces apoptosis in human lymphoma cells. Other applications include as a cell cycle arresting, apoptotic inducing alkaloid.
General Description
Vincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
Air & Water Reactions
Very hygroscopic. Water soluble.
Reactivity Profile
Sensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents. .
Fire Hazard
Flash point data for Vincristine sulfate are not available; however, Vincristine sulfate is probably combustible.
Biological Activity
Anticancer agent; microtubule disrupter. Induces apoptosis in human lymphoma cells.
Clinical Use
Vincristine sulfate is available as a 1-mg/mL solution in 1-,2-, and 5-mL vials for IV administration in acute leukemiaand as part of a multidrug regime for Hodgkin’s and neuroblastoma, Ewing sarcoma, Wilms tumor, soft tissuesarcoma, testicular cancer, liver cancer, and head and neckcancers. It has also been utilized in treating pediatric cancer.
Metabolism
Vincristine is metabolised in the liver by the cytochrome P450 isoenzymes CYP3A4 and CYP3A5 and excreted mainly in the bile; about 70-80 % of a dose is found in faeces, as unchanged drug and metabolites (40-50 %), while 10-20 % appears in the urine.
Vincristine is highly protein bound (75%) and may also bindto platelets that contain large amounts of tubulin. Numerousmetabolites have been detected and several have been identified,one of which is the 4-O-desacetyl derivative. The metabolismthat does occur is believed to largely be mediatedby CYP3A. Elimination occurs primarily in the bile with aterminal elimination half-life of 23 to 85 hours.
Purification Methods
The salt is recrystallised from MeOH. It has UV max at 220, 255 and 296nm (log 4.65, 4.21 and 4.18). It is a monoamine oxidase inhibitor and is used in cancer research [Son et al. J Med Chem 33 1845 1990, Horio et al. Proc Natl Acad Sci USA 85 3580 1988].
Mode of action
Vincristine Sulfate is the sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.
Toxicity evaluation
The mostcommonly seen toxicity for vincristine is a dose-limitingneurotoxicity caused by effects on axonal microtubules.Symptoms are variable and include peripheral neuropathy,ataxia, seizure, bone pain, and coma. Constipation is also acommonly seen toxicity, and laxatives may be used prophylactically.Other toxicities include alopecia, skin rash, mildmyelosuppression, secretion of antidiuretic hormone,azospermia, and amenorrhea.
Vincristine sulfate Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Cipla Ltd | +912224826000 | Maharashtra, India | 133 | 58 | Inquiry |
| Zyphars Biopharmaceuticals Pvt. Ltd | +91-8007587007 +91-8007587007 | Mumbai, India | 14 | 58 | Inquiry |
| BDR Pharmaceuticals International Pvt Ltd | +91-2240560560 +91-7718884418 | Maharashtra, India | 206 | 58 | Inquiry |
| CIPLA LIMITED | +91 22 24826000 | New Delhi, India | 72 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| Manus Aktteva | +91 (79) 6512-3395 | New Delhi, India | 581 | 34 | Inquiry |
| OCEAN TRADING CORPORATION | +91(22) 24921669 | New Delhi, India | 6211 | 58 | Inquiry |
2068-78-2(Vincristine sulfate)Related Search:
1of4
chevron_right